Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

Capricor Therapeutics Inc. CAPR) on Monday reported a loss of $25.9 million in its second quarter. On a per-share basis, the ...

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today ...

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, discusses recent Complete Response Letters issued to Replimune and Capricor, explaining how shifts in FDA reviewers can affect ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...

Capricor Therapeutics Second Quarter 2025 Financial Results and Recent Corporate Update Conference Call and Webcast Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 90328 ...

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: ...

Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S ...